Key result
Sodium-glucose co-transporter 2 (SGLT2) inhibitors and GLP-1 receptor agonists reduce the risk of arrhythmia in patients with diabetes.
Why the study?
Do SGLT2 inhibitors and GLP-1 receptor agonists reduce the risk of arrhythmia in patients with diabetes?
Do SGLT2 inhibitors and GLP-1 receptor agonists reduce the risk of arrhythmia in patients with diabetes?
SGLT2 inhibitors and GLP-1 receptor agonists may reduce the risk of arrhythmias in patients with diabetes, highlighting their potential cardiovascular benefits beyond glycemic control.
May warrant closer arrhythmia monitoring in DM; leaves open targeted interventions pending higher-level evidence.
<ns3:p>Diabetes mellitus (DM) is a severe public health problem. Patients with DM are at increased risk of cardiovascular disease and cardiac arrhythmias, such as atrial fibrillation, ventricular arrhythmias, and atrioventricular blocks. The pathophysiology of cardiac arrhythmias in patients with DM is complex and includes factors such as chronic hyperglycemia, hypoglycemia, oxidative stress, inflammation, myocardial fibrosis, and autonomic neuropathy. In treating arrhythmias, emphasis is placed on the need for aggressive treatment of cardiovascular risk factors and regular monitoring of patients for arrhythmias. Recent studies on pharmacological treatment indicate the benefits of using sodium-glucose co-transporter 2 (SGLT2) inhibitors and GLP-1 (glucagon-like peptide-1) receptor agonists in reducing the risk of arrhythmia in patients with diabetes.</ns3:p>
No takes yet. Share an insight, caveat, or question.
Pabis et al. (2025) conducted a review in Diabetes mellitus and cardiac arrhythmias. SGLT2 inhibitors and GLP-1 receptor agonists was evaluated on Risk of arrhythmia. Sodium-glucose co-transporter 2 (SGLT2) inhibitors and GLP-1 receptor agonists reduce the risk of arrhythmia in patients with diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: